Elizabeth Posillico
Direktor/Vorstandsmitglied bei Elusys Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jeff Wolf | M | 60 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
John Prendergast | M | 70 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
Edward Smith | M | 48 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
John Monahan | M | 77 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
Paul Tebbey | M | - |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Linda L. Nardone | M | 77 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 6 Jahre |
Frank E. Young | M | 92 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
Stephen G. Sudovar | M | 77 |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 6 Jahre |
Victor Paulus | M | - |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
Robert Gundel | M | - |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | - |
Stephen Haworth | M | - |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | 1 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 11 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Elizabeth Posillico
- Persönliches Netzwerk